Teduglutide (Revestive®)

Assessment Status Assessment process complete
Drug Teduglutide
Brand Revestive®
Indication For the treatment of patients aged 1 year and above with short bowel syndrome. Patients should be stable following a period of intestinal adaptation.
Assessment Process
Rapid review commissioned 13/03/2017
Rapid review completed 12/04/2017
Rapid review outcome Full Pharmacoeconomic Assessment Recommended.
Full pharmacoeconomic assessment commissioned by HSE 12/04/2017
Pre-submission consultation with Applicant 15/05/2017
Full submission received from Applicant 31/07/2017
Preliminary review sent to Applicant 21/11/2017
NCPE assessment re-commenced 05/12/2017
Factual accuracy sent to Applicant 06/02/2018
NCPE assessment re-commenced 21/02/2018
NCPE assessment completed 16/03/2018
NCPE assessment outcome Reimbursement Not Recommended.

Technical Summary

The HSE has approved reimbursement following confidential price negotiations January 2021.